Abiopharma

🔍 LeMaitre George W (Executive)

Company: LEMAITRE VASCULAR INC (LMAT)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Sold 18,600 shares of Common Stock at $107.6351 per share (Direct)
  Date: 2026-05-07 | Code: S | equity_swap_involved: false | shares_owned_after: 1,457,900.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 27,881 shares of Common Stock at $108.6905 per share (Direct)
  Date: 2026-05-08 | Code: S | equity_swap_involved: false | shares_owned_after: 1,430,019.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: H | nature_of_ownership: LEMAITRE IRREVOCABLE LIFE INSURANCE TRUST OF 2025 | shares_owned_after: 33,400.00 | Footnotes: F3

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $107.10 to $108.00. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
• F2: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $107.41 to $109.73. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
• F3: These shares are held by an irrevocable trust for the benefit of Reporting Person's child(ren). The Reporting Person disclaims ownership of such securities except to the extent of his pecuniary interest therein, if any, and the reporting herein of such securities shall not be construed as an admission of beneficial ownership thereof for the purposes of Section 16 or for any other purpose.